Physician profile
Alexis Manuel Cruz Chacon
NPI 1083898969
$450,431.48
in general payments reported to CMS, 2019-2025
62 companies · $64K in 2025
The $64K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $45K · 2021: $69K · 2022: $75K · 2023: $58K · 2024: $64K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Food and Beverage: $15K · Consulting Fee: $6,083 · Travel and Lodging: $3,440 · Honoraria: $2,340 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,325.18 |
| Food and Beverage | $14,609.84 |
| Consulting Fee | $6,083.00 |
| Travel and Lodging | $3,439.96 |
| Honoraria | $2,340.00 |
| Education | $320.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88,299.61 | 2019-2025 | Blincyto, Blincyto, Kyprolis |
| Janssen Pharmaceuticals, INC | $73,464.25 | 2019-2025 | Darzalex, Erleada, Talvey |
| Abbvie INC. | $69,149.61 | 2019-2025 | Venclexta, Epkinly |
| Glaxosmithkline, LLC. | $58,470.65 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Genzyme Corporation | $44,230.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39,896.56 | 2019-2024 | Iclusig, Advate, Vonvendi |
| E.R. Squibb & Sons, L.L.C. | $18,518.10 | 2019-2025 | Pomalyst, Reblozyl, Opdivo |
| Celgene Corporation | $16,570.80 | 2019-2022 | |
| Taiho Oncology, INC. | $14,677.84 | 2020-2025 | |
| Janssen Biotech, INC. | $4,531.70 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Sanofi-Aventis U.S. LLC | $3,476.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,150.24 | 2019-2025 | Calquence, Tagrisso, Imjudo |
| Rigel Pharmaceuticals, INC. | $2,871.37 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Merck Sharp & Dohme LLC | $1,779.87 | 2019-2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $1,701.83 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Cruz Chacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.